Overview

• Recent UKHSA data show the RSV vaccine prevents about 82% of hospitalisations in adults aged 75–79 and reduces infant admissions by around 72% when given to expectant mothers more than two weeks before birth
• Uptake among eligible older adults has risen to roughly 63% and to about 55% among pregnant women since the dual programme launched last September
• NHS England is sending invitations to adults aged 75–79 and offers the jab to pregnant women from 28 weeks through maternity services or GPs
• MHRA issued a July safety alert advising clinicians to watch for Guillain-Barré syndrome symptoms following RSV vaccination
• Health experts warn that record RSV cases in Australia signal a likely winter wave in the UK, underpinning the urgent push for higher coverage